-
Je něco špatně v tomto záznamu ?
Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis
MJ. Martínez-Gallardo, C. Villicaña, M. Yocupicio-Monroy, SL. Alcaraz-Estrada, J. León-Félix
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
- MeSH
- antibakteriální látky MeSH
- bakteriofágy * MeSH
- cystická fibróza * MeSH
- fágy pseudomonád * MeSH
- lidé MeSH
- pseudomonádové infekce * MeSH
- Pseudomonas aeruginosa MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Pseudomonas aeruginosa (PA) is considered the first causal agent of morbidity and mortality in people with cystic fibrosis (CF) disease. Multi-resistant strains have emerged due to prolonged treatment with specific antibiotics, so new alternatives have been sought for their control. In this context, there is a renewed interest in therapies based on bacteriophages (phages) supported by several studies suggesting that therapy based on lytic phages and biofilm degraders may be promising for the treatment of lung infections in CF patients. However, there is little clinical data about phage studies in CF and the effectiveness and safety in patients with this disease has not been clear. Therefore, studies regarding on phage characterization, selection, and evaluation in vitro and in vivo models will provide reliable information for designing effective cocktails, either using mixed phages or in combination with antibiotics, making a great progress in clinical research. Hence, this review focuses on the most relevant and recent findings on the activity of lytic phages against PA strains isolated from CF patients and hospital environments, and discusses perspectives on the use of phage therapy on the treatment of PA in CF patients.
CONACYT Centro de Investigación en Alimentación y Desarrollo A C Culiacán Sinaloa Mexico
Division of Genomic Medicine Centro Médico Nacional 20 de Noviembre ISSSTE Mexico City Mexico
Postgraduate in Genomic Sciences Universidad Autónoma de la Ciudad de México Mexico City Mexico
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23000901
- 003
- CZ-PrNML
- 005
- 20230307110408.0
- 007
- ta
- 008
- 230307s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-022-00990-5 $2 doi
- 035 __
- $a (PubMed)35931928
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Martínez-Gallardo, María José $u Laboratory of Molecular Biology and Functional Genomics, Centro de Investigación en Alimentación y Desarrollo, Culiacán, Sinaloa, A.C. (CIAD), Mexico $1 https://orcid.org/000000024724063X
- 245 10
- $a Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis / $c MJ. Martínez-Gallardo, C. Villicaña, M. Yocupicio-Monroy, SL. Alcaraz-Estrada, J. León-Félix
- 520 9_
- $a Pseudomonas aeruginosa (PA) is considered the first causal agent of morbidity and mortality in people with cystic fibrosis (CF) disease. Multi-resistant strains have emerged due to prolonged treatment with specific antibiotics, so new alternatives have been sought for their control. In this context, there is a renewed interest in therapies based on bacteriophages (phages) supported by several studies suggesting that therapy based on lytic phages and biofilm degraders may be promising for the treatment of lung infections in CF patients. However, there is little clinical data about phage studies in CF and the effectiveness and safety in patients with this disease has not been clear. Therefore, studies regarding on phage characterization, selection, and evaluation in vitro and in vivo models will provide reliable information for designing effective cocktails, either using mixed phages or in combination with antibiotics, making a great progress in clinical research. Hence, this review focuses on the most relevant and recent findings on the activity of lytic phages against PA strains isolated from CF patients and hospital environments, and discusses perspectives on the use of phage therapy on the treatment of PA in CF patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a bakteriofágy $7 D001435
- 650 _2
- $a Pseudomonas aeruginosa $7 D011550
- 650 12
- $a pseudomonádové infekce $7 D011552
- 650 12
- $a fágy pseudomonád $7 D017105
- 650 12
- $a cystická fibróza $7 D003550
- 650 _2
- $a antibakteriální látky $7 D000900
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Villicaña, Claudia $u CONACYT-Centro de Investigación en Alimentación y Desarrollo A.C. (CIAD), Culiacán, Sinaloa, Mexico $1 https://orcid.org/0000000237378416
- 700 1_
- $a Yocupicio-Monroy, Martha $u Postgraduate in Genomic Sciences, Universidad Autónoma de la Ciudad de México (UACM), Mexico City, Mexico $1 https://orcid.org/0000000178855656
- 700 1_
- $a Alcaraz-Estrada, Sofía Lizeth $u Division of Genomic Medicine, Centro Médico Nacional 20 de Noviembre-ISSSTE, Mexico City, Mexico $1 https://orcid.org/0000000191449193
- 700 1_
- $a León-Félix, Josefina $u Laboratory of Molecular Biology and Functional Genomics, Centro de Investigación en Alimentación y Desarrollo, Culiacán, Sinaloa, A.C. (CIAD), Mexico. ljosefina@ciad.mx $1 https://orcid.org/000000033755881X
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 68, č. 1 (2023), s. 1-16
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35931928 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230307 $b ABA008
- 991 __
- $a 20230307110403 $b ABA008
- 999 __
- $a ok $b bmc $g 1905270 $s 1187096
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 68 $c 1 $d 1-16 $e 20220805 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- LZP __
- $a Pubmed-20230307
